Shots:

• BioNTech to receive $135M as up front- future investment & milestone payments and $50M as an equity investment for 1-580-777 ordinary shares in BioNTech. Fosun to get the rights to commercialize BNT162 in China while BioNTech retain all rights of the vaccine in ROW
• The companies will jointly conduct clinical studies of BNT162 in China- leveraging BioNTech’s mRNA vaccine technology and Fosun’s clinical development and commercialization capabilities in China
• The companies will share profits from sales in China. Additionally- BioNtech with its partner Polymun will supply the mRNA vaccine for clinical studies from GMP manufacturing facilities in the EU

Click here ­to­ read full press release/ article | Ref: Business wire | Image: Businesswire